Statistics

Total Visits

Views
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase 299

Total Visits per Month

October 2020 November 2020 December 2020 January 2021 February 2021 March 2021 April 2021
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase 0 0 0 1 1 0 2

File Downloads

Views

Top Country Views

Views
United States 57
China 21
Germany 21
France 6
Australia 4
United Kingdom 2
Netherlands 1

Top City Views

Views
Mountain View 16
Ashburn 14
Beijing 14
Fairfield 7
Kaleen 3
N├╝rnberg 3
Adelaide 1
Putian 1
San Ramon 1
Seattle 1